MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562462 | Name: sEH-IN-12

Description:

WARNING: This product is for research use only, not for human or veterinary use.

sEH-IN-12 is a potent inhibitor of the enzyme soluble epoxide hydrolase (sEH).

Chemical Structure

sEH-IN-12
CAS#1883803-09-5

Theoretical Analysis

MedKoo Cat#: 562462

Name: sEH-IN-12

CAS#: 1883803-09-5

Chemical Formula: C25H29N5O2

Exact Mass: 431.2321

Molecular Weight: 431.54

Elemental Analysis: C, 69.58; H, 6.77; N, 16.23; O, 7.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
sEH-IN-12; sEH IN 12; sEHIN12; sEH inhibitor 12; sEH-inhibitor-12;
IUPAC/Chemical Name
N-(2-(1H-Pyrazol-1-yl)ethyl)-6-(3-(cyclohexylcarbamoyl)phenyl)-N-methylnicotinamide
InChi Key
WHWMQARWVOOSFY-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H29N5O2/c1-29(15-16-30-14-6-13-27-30)25(32)21-11-12-23(26-18-21)19-7-5-8-20(17-19)24(31)28-22-9-3-2-4-10-22/h5-8,11-14,17-18,22H,2-4,9-10,15-16H2,1H3,(H,28,31)
SMILES Code
O=C(N(CCN1N=CC=C1)C)C2=CN=C(C3=CC=CC(C(NC4CCCCC4)=O)=C3)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 431.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chang LH, Lin HC, Huang SS, Chen IC, Chu KW, Chih CL, Liang YW, Lee YC, Chen YY, Lee YH, Lee IH. Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation. Sci Rep. 2018 Jan 8;8(1):118. doi: 10.1038/s41598-017-18558-6. PubMed PMID: 29311641; PubMed Central PMCID: PMC5758800. 2: Yang SH, Kim YC, An JN, Kim JH, Lee J, Lee HY, Cho JY, Paik JH, Oh YK, Lim CS, Kim YS, Lee JP. Active maintenance of endothelial cells prevents kidney fibrosis. Kidney Res Clin Pract. 2017 Dec;36(4):329-341. doi: 10.23876/j.krcp.2017.36.4.329. Epub 2017 Dec 31. PubMed PMID: 29285425; PubMed Central PMCID: PMC5743042. 3: Hung TH, Shyue SK, Wu CH, Chen CC, Lin CC, Chang CF, Chen SF. Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury. Oncotarget. 2017 Sep 21;8(61):103236-103260. doi: 10.18632/oncotarget.21139. eCollection 2017 Nov 28. PubMed PMID: 29262558; PubMed Central PMCID: PMC5732724. 4: Kim HS, Kim SK, Kang KW. Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells. Int J Mol Sci. 2017 Dec 11;18(12). pii: E2683. doi: 10.3390/ijms18122683. PubMed PMID: 29232926; PubMed Central PMCID: PMC5751285. 5: Piotrowski J, Jędrzejewski T, Pawlikowska M, Pacuła AJ, Ścianowski J, Kozak W. The weakening effect of soluble epoxide hydrolase inhibitor AUDA on febrile response to lipopolysaccharide and turpentine in rat. J Physiol Biochem. 2017 Nov;73(4):551-560. doi: 10.1007/s13105-017-0584-y. Epub 2017 Jul 24. PubMed PMID: 28741242; PubMed Central PMCID: PMC5653702. 6: Tain YL, Lee WC, Wu KLH, Leu S, Chan JYH. Targeting arachidonic acid pathway to prevent programmed hypertension in maternal fructose-fed male adult rat offspring. J Nutr Biochem. 2016 Dec;38:86-92. doi: 10.1016/j.jnutbio.2016.08.006. Epub 2016 Sep 7. PubMed PMID: 27732913. 7: Lu PC, Sheen JM, Yu HR, Lin YJ, Chen CC, Tiao MM, Tsai CC, Huang LT, Tain YL. Early postnatal treatment with soluble epoxide hydrolase inhibitor or 15-deoxy-Δ(12,14)-prostagandin J2 prevents prenatal dexamethasone and postnatal high saturated fat diet induced programmed hypertension in adult rat offspring. Prostaglandins Other Lipid Mediat. 2016 Jul;124:1-8. doi: 10.1016/j.prostaglandins.2016.05.005. Epub 2016 May 19. PubMed PMID: 27210044. 8: Wu HF, Yen HJ, Huang CC, Lee YC, Wu SZ, Lee TS, Lin HC. Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex. J Biomed Sci. 2015 Oct 22;22:94. doi: 10.1186/s12929-015-0202-7. PubMed PMID: 26494028; PubMed Central PMCID: PMC4618874. 9: Zhang J, Liu YS, Lu QH. Therapeutic effects of the soluble epoxide hydrolase (sEH) inhibitor AUDA on atherosclerotic diseases. Pharmazie. 2015 Jan;70(1):24-8. PubMed PMID: 25975094. 10: Lee JP, Yang SH, Lee HY, Kim B, Cho JY, Paik JH, Oh YJ, Kim DK, Lim CS, Kim YS. Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney. PLoS One. 2012;7(5):e37075. doi: 10.1371/journal.pone.0037075. Epub 2012 May 10. PubMed PMID: 22590647; PubMed Central PMCID: PMC3349654. 11: Liu Y, Zhang J, Yu L, Cao F, Rao J, Li J, Jiang C, Falck JR, Jacobs ER, Zhu D. A soluble epoxide hydrolase inhibitor--8-HUDE increases pulmonary vasoconstriction through inhibition of K(ATP) channels. Pulm Pharmacol Ther. 2012 Feb;25(1):69-76. doi: 10.1016/j.pupt.2011.11.005. Epub 2011 Dec 3. PubMed PMID: 22155000. 12: Gao J, Bellien J, Gomez E, Henry JP, Dautreaux B, Bounoure F, Skiba M, Thuillez C, Richard V. Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension. J Hypertens. 2011 Jun;29(6):1128-35. doi: 10.1097/HJH.0b013e328345ef7b. PubMed PMID: 21451419. 13: Koeners MP, Wesseling S, Ulu A, Sepúlveda RL, Morisseau C, Braam B, Hammock BD, Joles JA. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats. Am J Physiol Endocrinol Metab. 2011 Apr;300(4):E691-8. doi: 10.1152/ajpendo.00710.2010. Epub 2011 Jan 25. PubMed PMID: 21266668; PubMed Central PMCID: PMC3074945. 14: Bukhari IA, Gauthier KM, Jagadeesh SG, Sangras B, Falck JR, Campbell WB. 14,15-Dihydroxy-eicosa-5(Z)-enoic acid selectively inhibits 14,15-epoxyeicosatrienoic acid-induced relaxations in bovine coronary arteries. J Pharmacol Exp Ther. 2011 Jan;336(1):47-55. doi: 10.1124/jpet.110.169797. Epub 2010 Sep 29. PubMed PMID: 20881018; PubMed Central PMCID: PMC3014297. 15: Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci. 2008 May 1;13:3480-7. PubMed PMID: 18508449. 16: Chawengsub Y, Aggarwal NT, Nithipatikom K, Gauthier KM, Anjaiah S, Hammock BD, Falck JR, Campbell WB. Identification of 15-hydroxy-11,12-epoxyeicosatrienoic acid as a vasoactive 15-lipoxygenase metabolite in rabbit aorta. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1348-56. doi: 10.1152/ajpheart.01326.2007. Epub 2008 Jan 11. PubMed PMID: 18192225. 17: Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab. 2007 Dec;27(12):1931-40. Epub 2007 Apr 18. PubMed PMID: 17440491; PubMed Central PMCID: PMC2664093. 18: Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther. 2006 Sep;318(3):1307-14. Epub 2006 Jun 13. PubMed PMID: 16772540. 19: Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2005 Dec;46(6):842-8. PubMed PMID: 16306811; PubMed Central PMCID: PMC1444897. 20: Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005 Oct;46(4):975-81. Epub 2005 Sep 12. PubMed PMID: 16157792; PubMed Central PMCID: PMC1444888.